Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05390827 · ClinicalTrials.gov registry record
Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
A clinical trial of Solid Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 3,644
- Enrollment target
- 1
- Study location
NCT05390827 is a study of Solid Tumor that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 3,644 participants, above the 203-participant average among 196 other Solid Tumor trials with a reported enrollment target (1695% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05390827, a study of Solid Tumor, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 3,644 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead to higher or lower risk of cancer.
Conditions Studied
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,644 participants |
| Start Date | 2022-05-19 |
| Est. Completion | 2027-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05390827
The ClinicalTrials.gov registry entry for NCT05390827 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 3,644 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 196 other Solid Tumor trials with a reported enrollment target (1695% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT05390827 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05390827 about?
NCT05390827 is a clinical study titled "Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol". The purpose of this study is to develop a secure method of collecting physiologic information from patients with cancer. The researchers will use this information to learn more about how physiologic data may relate to cancer diagnosis and response to treatment, and to identify factors that may lead ...
What is the current status of trial NCT05390827?
This trial is currently recruiting. The enrollment target is 3,644 participants. The study started on 2022-05-19. Estimated completion is 2027-07.
What conditions does trial NCT05390827 study?
This clinical trial studies the following conditions: Solid Tumor.
Who is sponsoring clinical trial NCT05390827?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05390827 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
RECRUITING · Phase 3
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.